Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $52.3 million versus the consensus estimate of $49 million.

• reaffirmed its fiscal 2018 guidance of per share diluted earnings between $0.59 and $0.62 on a GAAP basis (between $0.65 and $0.68 on a non-GAAP basis) on net revenues of $207 million to $212 million, before the impact of the tax reform act.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.